Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Biological: TUR01Biological: Adalimumab-EU
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- Turgut İlaçları A.Ş.
- Target Recruit Count
- 168
- Registration Number
- NCT04439929
- Locations
- 🇩🇪
PAREXEL International GmbH, Early Phase Clinical Unit Berlin, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath